Family history of cancer is a well-known risk factor but the role of family history in survival is less clear. The aim of this study was to investigate the association between family history and cancer survival for the common cancers in Sweden. Using the Swedish population-based registers, patients diagnosed with the most common cancers were followed for cancer-specific death during 1991-2010. We used multivariate proportional hazards (Cox) regression models to contrast the survival of patients with a family history of cancer (individuals whose parent or sibling had a concordant cancer) to the survival of patients without a family history. Family history of cancer had a modest protective effect on survival for breast cancer (hazard ratio (HR) 5 0.88, 95% confidence interval (95% CI) 5 0.81 to 0.96) and prostate cancer (HR 5 0.82, 95% CI 5 0.75 to 0.90). In contrast, family history of cancer was associated with worse survival for nervous system cancers (HR 5 1.24, 95% CI 5 1.05 to 1.47) and ovarian cancer (HR 5 1.20, 95% CI 5 1.01 to 1.43). Furthermore, the poorer survival for ovarian cancer was consistent with a higher FIGO stage and a greater proportion of more aggressive tumors of the serous type. The better survival for patients with a family history of breast and prostate cancer may be due to medical surveillance of family members. The poor survival for ovarian cancer patients with an affected mother or sister is multifactorial, suggesting that these cancers are more aggressive than their sporadic counterparts.
Introduction
Family history of cancer is considered an important risk factor and extensive work has been done to understand the risk associated with a family history for different cancers. [1] [2] [3] [4] In addition to the risk of developing cancer, family history of cancer survival has been suggested to be important for the cancer survival of a newly diagnosed individual. 5 We have previously shown that survival from cancer is in part inherited. 6, 7 One potential explanation for the association of survival among family members could be that relatives are at higher risk to develop a cancer tumor of predefined biology. Indeed, it has been shown that carriers of mutations in highrisk genes are more likely to develop a specific subtype of cancer. 8 It is also possible that the survival concordance in families is related to the inheritance of host characteristics for instance affecting the ability to mount an effective anti-tumoral immune response or respond to cancer therapy. 9 Furthermore, shared characteristics such as health-seeking behavior, treatment choices and life-style, are likely to be important for explaining the survival similarities among relatives. 10 Although we and others have investigated the concordance of survival in families, much less is known about differences in survival for patients with a family history of cancer as compared to patients without a family history (sporadic cancer). 11, 12 Therefore our aim in this study was to determine whether patients with a family history of cancer have a differential survival as compared to patients without a family history of cancer. Using Swedish population-based registers, we studied familial cancers with sufficient sample sizes to consider the kinship of affected relatives. For those cancers with any significant association, we explored in depth the effect of age at diagnosis and the histological tumor type on survival differences, and examined the association between stage information at diagnosis and family history of cancer.
Materials and Methods

Data sources
The data for this study is from a linkage of several Swedish population-based registers that has been described previously. 4 Individuals included in this study are all recorded in the Swedish Cancer Register with a first primary malignancy from January 1, 1991 to December 31, 2009 . To obtain the exposure information (i.e., family history of cancer), these patients are linked to their first degree relatives in the Swedish MultiGeneration Register. The Swedish Multi-Generation Register records the biological parents for all children born in Sweden from 1932 who were alive in 1961, with essentially complete parental information from 1991. 13 The cancer diagnoses of these family members were obtained from the Swedish Cancer Register (which was established in 1958 14 )
. We selected two cohorts of children for analysis: The first cohort included individuals with both biological parents identified (to investigate the effect of parental cancer history on survival), and the second cohort included individuals with at least one sibling (to investigate sibling effects). We followed these individuals for cancer-specific death in the Cause of Death Register which was available up to the end of 2010 with a reported accuracy of 96%. 6 Some additional information for censoring (date of emigration) was obtained from the Total Population Register and socioeconomic status was obtained from the census files from 1960, 1970, 1980, 1990 .
Cancers studied
The Swedish Cancer Register records all malignant cancers diagnosed since 1958 according to the seventh revision of the International Classification of Disease (ICD7). We included cancers that provided a sufficient sample size to address our hypotheses, namely stomach (ICD7 Our outcome variable, cancer-specific death, was defined by the underlying cause of death in the Swedish Cause of Death Register which is recorded using ICD codes. Our main exposure, family history of cancer, was defined as having at least one parent or sibling with a record of a diagnosis of a concordant cancer. The region in which the cancer diagnosis was registered, which was available from the Swedish Cancer Register, was classified as six medical regions. 18 The socioeconomic status from the Census data was grouped into five categories; blue-collar workers, white collar workers, self-employed workers, farmers and unclassified.
Statistical methods
Our main analyses compared the cancer-specific survival for up to 5-years after diagnosis for patients with and without a family history of cancer. Using multivariate proportional hazards (Cox) regression models, we estimated the hazard ratio (HR) of cancer-specific death for patients with a family history of the specific cancer as compared to patients without a family history (the reference group). In these analyses we adjusted for gender, age and calendar year of diagnosis, socioeconomic status and the region where the individual was diagnosed with cancer. Survival time was defined as the elapsed time from the date of What's new? Family history of cancer is a well-known risk factor for malignant disease. Yet, whether inherited characteristics, such as variations in therapeutic response, or behavioral factors shared with relatives also influence cancer survival is uncertain. In the present study, the influence of family history on cancer survival was investigated using data from cancer registries in Sweden. Analyses show that family history is a prognostic factor for cancers of certain histological types and at certain anatomical sites. In particular, family history played a protective role in breast and prostate cancer survival but was associated with poor survival in ovarian cancer.
cancer diagnosis until the date of cancer-specific death or censoring (death due to other causes, emigration, end of study, or 31 December 2010, whichever occurred first) within 5 years of diagnosis. If there was no other censoring event, patients were censored at 5 years after diagnosis. We also conducted stratified analyses by type of relationship (affected parent or sibling), age at diagnosis (classified as above or below the median) and by the specific histological type of cancer (subtype for leukemia). Because any difference in survival between patients with a family history and patients without a family history might be due to differences in histology distribution or differential survival within histological type, we compared the distribution of the histological type in the familial and sporadic cases (for the period from 1993 when SNOMED codes became available) and estimated the mortality in the 5 years following diagnosis for each histological type. Leukemia subtypes defined using the fourth digit of the ICD7 code 3 were analyzed for the same period. In addition, we investigated whether there is a differential survival for patients with a family history compared to patients without a family history of cancer associated with stage (TNM stage at cancer diagnosis for stomach, breast and prostate cancers, or with FIGO stage for ovarian cancer). For this analysis, we performed a logistic regression with stage information as outcome, family cancer history as the main exposure, and adjusting for sex, age at diagnosis, year of diagnosis, socioeconomic status and region. We present odds ratios (ORs) that provide a measure of the frequency of combined higher categories of stage relative to the lowest category in patients with a family history compared with patients without a family history of concordant cancer (i.e., T2-T4 vs. T1). Where there were any significant differences, we investigated each of the higher categories separately. These analyses were conducted for the period from 2004 when stage information was available.
All data preparation and analyses were performed using the SAS statistical package, version 9.4 (SAS Institute, Cary NC). 21 
Results
The study population for each cancer investigated is described in Table 1 , including the total number of patients diagnosed with the cancer, number of cancer-specific deaths and median age at diagnosis.
In Table 2 , we present the hazard ratios of cancer-specific death within 5 years for cancer patients with a family history compared to cancer patients without a family history. For breast cancer, prostate cancer and leukemia, we found that a concordant family cancer history played a protective role for cancer survival in patients: hazard ratio (HR) was 0.88, (95% confidence interval (CI) 5 0.81-0.96) for breast cancer, HR 5 0.82, (95% CI 5 0.75-0.90) for prostate cancer, and HR 5 0.70, (95% CI 5 0.54-0.92) for leukemia. In contrast, familial cancer patients had worse survival for patients with ovarian cancer and nervous system cancer: HR 5 1.20, (95% CI 5 1.01-1.43) and HR 5 1.24, (95% CI 5 1.05-1.47), respectively.
For the six cancers that had any significant association, in Table 2 , we further investigated the role of age, kinship, and histological type in the differential cancer survival. For breast and prostate cancer and leukemia, the protective effect was strongest in younger patients (Table 3 , last column). Familial ovarian cancer patients who were diagnosed at younger ages had consistently significantly higher risk of death in the 5 years after the cancer diagnosis than patients with sporadic cancer, HR 5 1.44, (95% CI 5 1.14-1.81) and the relative risk was highest when a sister was affected, HR 5 1.75, (95% CI 5 1.23-2.49).
Comparing the distribution of the histological type between familial and sporadic cancers, we found significant differences for breast cancer, ovarian cancer and leukemia (Table 4 , last five columns). Lobular breast cancer, which has a lower mortality rate than the more common ductal type, was slightly more common in breast cancer patients with a family history than in patients without a family history, 14.1% versus 12.8% (p 5 0.015). Serous ovarian cancer was more often detected in familial cancer patients (54.8% for familial cancer patients vs. 43.3% for sporadic cancer patients) (p 5 0.001) and the very high mortality rate for serous ovarian cancer thus contributes to the higher risk of cancer death in familial ovarian cancer patients. Lymphatic leukemia was more common among familial cases of adult leukemia (p < 0.001) and the lower mortality rate for this subtype thus explains in part the protective effect of family history.
The associations between family cancer history and survival for each specific histological type of cancer are presented in Table 5 . For ductal breast cancer and adenocarcinoma of the stomach and prostate, patients with a family history had better survival than patients without a family history with the same histological type (HR ranging from 0.80 to 0.86). However, for mucinous ovarian cancer, patients whose mother or sister was diagnosed with the same cancer had twice the risk of death compared to sporadic cancer patients, HR 5 2.09, (95% CI 5 1.09-3.98). For nervous system cancer, patients with a family history had much worse survival than patients without a family history when their cancer was gliomas of uncertain origin, HR 5 2.78, (95% CI 5 1.16-6.65) or classified as 'other' histological type, HR 5 2.35, (95% CI 5 1.12-4.93).
Finally, we explored the stage information at diagnosis in patients with a family history and patients without a family history of concordant cancer (Table 6 ). Prostate cancer patients with a family history were less likely to be diagnosed with tumors of larger size/extent compared to patients without a family history (p 5 0.006). Family cancer history of prostate cancer was associated with a reduction of 11% in the odds of tumors diagnosed in the T3 category (OR 5 0.89, 95% CI 5 0.81 to 0.97, T3 vs. T1), consistent with the protective effect we observed for family history. We observed a large and significant increase in the odds of higher FIGO stages vs. Although there was no significant difference in TNM stage in breast cancer patients with and without a family history of breast cancer, we implemented additional analysis for the two main histological types (ductal and lobular) which had sufficient number of cases (Supporting Information Table 1 ). For ductal breast cancer, patients with family history of breast cancer tended to be diagnosed with smaller tumor size (p 5 0.01) with an OR of 0.88, (95% CI 5 0.78-0.98) for T2-T4 vs. T1. For lobular breast cancer, a family cancer history of breast cancer was associated with an increase in the odds of positive nodal involvement vs. negative nodal involvement: OR 5 1.33, (95% CI 5 1.02-1.73).
Discussion
We have demonstrated a different role for family history of cancer in cancer survival for 5 years after diagnosis depending on the cancer site; a protective effect for stomach cancer, breast cancer, prostate cancer and leukemia but a poorer survival for ovarian cancer and nervous system cancers. No associations were found for lung cancer, kidney cancer, bladder cancer, melanoma or non-Hodgkin's lymphoma. The potential explanations for the differential survival varied with cancer site: earlier stage at diagnosis for familial prostate cancer, a higher proportion of a less aggressive subtype for familial leukemia and differential survival within histological type of nervous system cancers. For ovarian cancer, the much poorer survival for familial cancers had a contribution from all of these factors, reflecting highly aggressive tumors in familial cases and suggesting that these may have a distinct genetic profile that has not yet been characterized.
Because each cancer has a different prognosis, we chose to focus on the 5-year interval following diagnosis, as this is common in cancer recurrence and survivorship studies. 22 However, breast cancer and prostate cancer have much lower mortality than the other cancers studied (Table 4) so that a longer period of follow-up would be more appropriate. We repeated our comparison of familial and non-familial breast and prostate cancer using all available follow-up time and none of these analyses changed our current conclusions (Supporting Information Table 2 ) In sensitivity analyses, we compared cancer-specific overall survival after diagnosis for familial cancer patients to the cancer-specific overall survival of sporadic cancer patients and also implemented our analyses on a wider cohort of cancer patients diagnosed during 1961-2009, and these analyses did not change our current conclusion (data not shown).
For most common cancers, few systematic and detailed investigations of survival differences between familial and sporadic cancer have been done previously, but our findings are consistent with earlier studies on familial survival for stomach cancer, ovarian cancer and bladder cancer. 11, 12, 23, 24 Recently, Kharazmi et al. (2016) compared survival in familial and nonfamilial breast cancer by age and stage at diagnosis using the Swedish Family-Cancer Database. 25 They found no evidence for familial breast cancer diagnosis at an earlier TNM stage compared to sporadic cases, which is in line with our findings in Table 6 . However, we did find evidence that for ductal breast cancer, familial cases are diagnosed with smaller tumor size, consistent with the survival advantage we observed. In addition, our histology-specific mortality rates were largely in agreement with the literature on cancer survival, with poorer survival for ductal breast cancer, 26, 27 signet ring stomach cancer, 28 non-adenocarcinoma prostate cancer, 29 serous ovarian cancer, 11 astrocytic nervous system cancers and gliomas of uncertain origin, 30 and a significantly better survival for lymphatic leukemia than for other subtypes. 31 A small survival benefit was seen in patients with a family history of breast cancer in our study, which was more pronounced if the affected relative was a sister. Thus, even with nationwide mammographic screening since the 1990 sec in Sweden, 32 this finding suggests earlier detection due to increased awareness and positive medical surveillance in women with a family history of breast cancer. Such lead time bias was apparent for ductal breast cancer, the most common histological type, where we found that patients with a family history were more often diagnosed with smaller tumors. In contrast, for lobular breast cancer, which accounted for approximately 13% of all breast cancers and is harder to detect by mammography, 27 familial cases tended to have larger tumor sizes and cases were at increased risk to be diagnosed with lymph node positive tumors. While this suggests a more aggressive disease in familial lobular breast cancer, there was no evidence of a higher cancer-specific mortality in familial cases. A possible interpretation is that familial lobular cancer is somehow different than sporadic and that more research of this specific histological type is needed, in particular since it is known to be hard to detect through mammographic screening.
Even though some early studies suggested that familial disease may have a more aggressive course in prostate cancer, the overall data suggest that the survival of patients with a family history is not essentially different from that of patients without a family history of prostate cancer. [33] [34] [35] Prostate-specific antigen (PSA) testing has been suggested to be one of the reasons for the inconsistent results. 33 PSA testing was introduced in Sweden in the mid-1990 sec with a rise in incidence reported after this time. 36 In a previous study, we reported a significantly increased risk of prostate cancer diagnosis shortly after a diagnosis in a brother in the calendar period after the introduction of PSA testing. 4 Because prostate cancer has a long lead time, 37 this suggests that sons or brothers of prostate cancer patients may be more likely to seek medical attention and thus have higher probability of early detection due to the opportunistic screening, which in turn will contribute to a protective effect of family history such as we observed. We also found a significantly reduced risk of familial prostate cancer patients being diagnosed with a larger tumor, again reflecting lead-time bias in these patients. The protective effect of family history for leukemia is consistent with the preponderance of lymphatic leukemia, which is well known to be more familial than other subtypes, [38] [39] [40] and the better survival of this subtype. Hazard ratio (HR) with 95% confidence interval (C.I.) from Cox regression model adjusting for sex, age at diagnosis, year of diagnosis, socioeconomic status and region of cancer diagnosis. 2 Sex-specific cancers. 3 Excluded childhood cancers (diagnosis at age 0-14 years).
Cancer Epidemiology
Lee et al. Hazard ratio (HR) with 95% confidence interval (C.I.) from Cox regression model adjusting for sex, age at diagnosis, year of diagnosis, socioeconomic status and region of cancer diagnosis. 2 Sex-specific cancers. 3 Excluded childhood cancers (diagnosis at age 0-14 years).
Cancer Epidemiology Our findings of a poor survival in women with a family history of ovarian cancer are in agreement with previous studies. 11, 23 We found familial ovarian cancer patients who were diagnosed before 55 years of age had consistently significantly higher risk of death in the 5 years after the cancer diagnosis compared to patients with sporadic cancer. This might be due to germline mutations relevant to ovarian cancer. 41 A contributing factor to the differences in survival for familial and sporadic cases of ovarian cancer is the distribution of histological types. In agreement with previous studies, 42 we found serous ovarian cancer to be more familial than other histological types and BRCA1 or BRCA2 carriers are more likely to have this histology. 43, 44 Because the survival is poorer for serous histology than for other subtypes, 11 this results in a higher risk of cancer death for familial cancers. However, for patients with serous ovarian cancer we found no evidence that family cancer history had any further effect on survival, in agreement with previous reports indicating that women with BRCA1/BRCA2 mutations can even have a survival advantage. 43, 44 On the contrary, patients with familial mucinous ovarian cancer, who are not BRCA1 or BRCA2 mutation carriers, 44 have 1 Hazard ratio (HR) with 95% confidence interval (C.I.) is from Cox regression model adjusting for sex, age at diagnosis, year of diagnosis, socioeconomic status and region of cancer diagnosis. 2 Sex-specific cancers. 3 Excluded childhood cancers (diagnosis at age 0-14 years).
increased risk of death in our data, possibly suggesting germline mutations associated with prognosis or therapy response. Because a reasonable proportion of ovarian cancers are mucinous, the differential survival for this histology type adds further to the risk of death associated with family history. We also observed that ovarian cancer patients with a family history were more likely to be diagnosed with tumor of higher FIGO stage than patients without a family history. In the absence of any available diagnostic test to date with sufficient accuracy to identify early-stage ovarian cancer, 45 this is again consistent with more aggressive tumors in familial cases.
For nervous system cancers, we found astrocytic histology to have the worst mortality rates, followed by gliomas of uncertain origin, findings that are in agreement with other studies. 30 Although the distribution of histological types was similar among patients with a family history and patients without a family history, the familial cancer patients with gliomas of uncertain origin had poorer survival than sporadic cancer patients.
Strengths of this study include the use of Swedish population-based registers that have almost complete ascertainment of cancer cases providing an unbiased assessment of family history and long follow-up. The Swedish national cancer register has been validated and shown to have a high level of completeness (98%). 18 In addition, the availability of information on detailed histological type and stage enables us to explore these factors in an effort to elucidate any noted differences in survival for familial and sporadic cancer patients.
Despite the positive aspects of our study, the study also has several limitations. First, the Swedish Cancer Register contains no information on treatment, which might affect survival. However, it is unlikely that differential treatments are provided to familial and nonfamilial cancer patients in Sweden, where the public health system provides similar treatment to all patients according to general guidelines. 25 Nonetheless, regional differences in treatment might exist. Therefore, we adjusted all our models for the region where the patient was diagnosed. Changes in diagnosis and treatment protocols over time might also affect survival, and in an effort to adjust for these changes we also adjusted our models for calendar year of cancer diagnosis. Another limitation of our study is that there is no information on important risk factors such as obesity, alcohol consumption and smoking.
In conclusion, our findings provide evidence that family history of cancer is a prognostic factor for cancers at some sites and histological type of cancer also has further prognostic value. Further work is needed to understand the role of screening in family members. The strong association of more aggressive ovarian cancers in sisters and daughters of patients diagnosed with ovarian cancer may be informative for genetic counseling and help to guide further molecular or genetic investigations. Odds ratio (OR) and associated 95% confidence intervals (C.I.) for familial cancer patients vs. sporadic cancer patients are adjusted for sex, age at diagnosis, year of diagnosis, socioeconomic sta-
